CWP
ARKG icon

Concord Wealth Partners’s ARK Genomic Revolution ETF ARKG Stock Holding History

Concord Wealth Partners’s Portfolio ARKG Stock Details ARKG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-114
Closed -$4K – 217
2022
Q2 		$4K Buy
114
+14
+14% +$490 ﹤0.01% 848
2022
Q1 		$5K Hold
100
– – ﹤0.01% 895
2021
Q4 		$6K Hold
100
– – ﹤0.01% 892
2021
Q3 		$7K Hold
100
– – ﹤0.01% 523
2021
Q2 		$9K Hold
100
– – ﹤0.01% 635
2021
Q1 		$9K Hold
100
– – ﹤0.01% 592
2020
Q4 		$9K Buy
+100
New +$7.97K 0.01% 366

Other funds holding ARKG

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
State of Wisconsin Investment Board
State of Wisconsin Investment Board Madison, Wisconsin $49.6B AUM 39.59% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Concord Wealth Partners's ARKG Position: Q3 2022 in Review

Concord Wealth Partners sold out of ARK Genomic Revolution ETF (ARKG) in Q3 2022, closing a stake of 114 shares — an estimated $4K sold.

Concord Wealth Partners first reported a position in ARKG in Q4 2020 and held it in 7 quarters. The position peaked at $9K in Q2 2021. 312 funds tracked by Wall St. Rank hold ARKG as of Q3 2022.

  • Concord Wealth Partners reported no remaining ARK Genomic Revolution ETF position as of Q3 2022 after selling out during the quarter.
  • Concord Wealth Partners sold 114 ARK Genomic Revolution ETF shares in Q3 2022, an estimated $4K.
  • Concord Wealth Partners first reported a position in ARK Genomic Revolution ETF in Q4 2020 and held it in 7 quarters.
  • Concord Wealth Partners's ARK Genomic Revolution ETF position peaked at $9K in Q2 2021.
  • 312 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q3 2022.

Based on Concord Wealth Partners's 13F filing for Q3 2022, filed 10 Nov 2022.